M
Memento Medicines
Biotech & Life Sciences · Boston, United States · Founded 2026
Bispecific antibody therapies for retinal vascular diseases. MoreLess
Memento Medicines is a Boston-based biotechnology company developing biologic therapies for retinal and vascular diseases. Its lead program, MMT-205 (formerly MT-103), is an investigational bispecific antibody that simultaneously activates the Tie2 receptor and inhibits the VEGF pathway, two clinically validated targets in retinal disease. The company is advancing MMT-205 toward IND-enabling studies in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), with clinical trials expected to begin in 2027. Memento licensed worldwide rights to the asset from MabTics and Curacle, and is one of the subsidiaries financed by Sera Medicines, an antibody accelerator formed with RA Capital Management.
Company overview
Memento Medicines company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2026
- Headquarters
- Boston, United States
- Employees
- —
- Open positions
- None listed
- Dealroom signal
- 18.7
Valuation & funding
Memento Medicines funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jun 2026 | $93M | $372M | Forbion Capital Partners · Sanofi Ventures · Samsara BioCapital · RA Capital Management | ↗ |
Comparisons
Memento Medicines compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 OtusOphtaLipid-based technology for treating dry eye disease |
Helsinki, Finland | Operational | — | — | — |
 CuracleOral therapeutics for age-related intractable vascular diseases |
Seoul, South Korea | Operational | |||
 Ascentia Asset ManagementInvestment fund for development-stage biotechnology companies. |
Waltham, United States | Operational | |||
 SEQOVACross-border pharma and biotech asset partnerships. |
Prague, Czechia | Operational | |||
 Lorikeet TherapeuticsInsulin-independent glucose uptake therapies for Type 1 Diabetes. |
Ringwood, Australia | Operational | |||
 Celea TherapeuticsTherapeutics for serious and progressive respiratory diseases. |
Boston, United States | Operational | |||
 Navegador BiosciencesPreclinical drug development programs for clinical success. |
Portugal | Operational | |||
 Ashta TherapeuticsSmall molecule compounds for difficult-to-treat diseases. |
India | Operational |
Talent graph
Memento Medicines's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Memento Medicines has talent and traffic
In the news
Latest news about Memento Medicines
Recent press, funding announcements, and product moves mentioning Memento Medicines — open to read from the original sources.
Market sentiment
What the market is saying about Memento Medicines
An AI-synthesized read of the highest-engagement posts about Memento Medicines on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Memento Medicines’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.